ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1015

Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals

Emma Van Lieshout1, Dennisse Bonilla 2, Zahi Touma 3, Arthur Bookman 4, Linda Hiraki 5, Zareen Ahmad 6, Sindhu Johnson 7, Earl D. Silverman 8 and Joan Wither 9, 1University of Toronto, Toronto, ON, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, Canada, 4University Health Network - Toronto Western Hospital, Toronto, Canada, 5The Hospital for Sick Children, Toronto, Canada, 6Mount Sinai Hospital, Toronto, Canada, 7Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, 8Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, 9University Health Network, Krembil Research Institute, Toronto, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antinuclear antibodies (ANA), autoimmune diseases and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) including Sjogren’s Disease (SjD), Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE) are characterized by the production of anti-nuclear antibodies (ANA) and are associated with considerable morbidity and/or mortality. ANA production can also be seen in ~20% healthy women, only a small subset of which will eventually progress to a SARD diagnosis. Although pro-inflammatory cytokines including TNFα and IL-6 are only increased in symptomatic patients, some of the cellular immune changes associated with SARD are also seen in ANA+ non-symptomatic (ANA+ NS) individuals. In order to better understand the immunologic changes that lead to SARD progression, we used flow cytometry to investigate a variety of innate and adaptive immune populations in ANA+ NS as compared to healthy controls (HC) and SARD patients.

Methods: Consenting ANA+ (IF ≥ 1:160) participants were recruited through the clinic and classified as ANA+ NS (n = 38), ANA+ with symptoms but lacking sufficient criteria for SARD diagnosis (UCTD, n=42) or early SARD (SLE, n=5, SSc, n=2). SARD diagnosis and classification was assessed according to the 1997 ACR criteria for SLE and the 2013 ACR-EULAR criteria for SSc. All SARD patients were within 2 years of diagnosis and not taking DMARDs (hydroxychloroquine allowed) or prednisone. ANA– HC (n= 14) were also recruited. Peripheral blood mononuclear cells (PMBCs) were isolated and stained with fluorochrome labeled antibodies to identify immune cell populations via flow cytometry.

Results: Several of the immunologic changes previously reported for SARD patients were also seen in ANA+ NS and UCTD. These included: increased proportions of plasma cells and plasmablasts; a trend to increased transitional B cells, activated class-switch memory B cells, activated memory Tfh and Tph cells; and a trend towards decreased proportions class-switched memory B cells. Contrary to initial reports that T regulatory (Treg) cells are decreased in SARD, these cells were increased in ANA+ NS and UCTD groups with similar changes seen for the SARD patients. However, a subset of regulatory cells, CD8 Treg were markedly decreased in ANA+ NS and UCTD patients, suggesting a potential functional role for these cells in regulating autoimmunity. Monocytes and myeloid dendritic cells are increased in SARD patients and have been shown to produce pro-inflammatory cytokines. These populations were also significantly increased in ANA+ NS and to a lesser extent in UCTD patients, as compared to HC. In contrast, no changes were seen in the proportion of plasmacytoid dendritic cells in ANA+ NS and UCTD patients.

Conclusion: Several of the immune changes in ANA+ NS individuals appear to parallel those seen in SARD patients, indicating that there is substantial immune activation even in asymptomatic ANA+ individuals. These findings argue that the differences between ANA+ NS and SARD patients may result from altered function rather than altered proportions of these populations.


Disclosure: E. Van Lieshout, None; D. Bonilla, None; Z. Touma, None; A. Bookman, None; L. Hiraki, None; Z. Ahmad, None; S. Johnson, Bayer, 2, Boehringer Ingelheim, 2, 5, Corbus, 2, Ikaria, 5, Roche, 2; E. Silverman, None; J. Wither, None.

To cite this abstract in AMA style:

Van Lieshout E, Bonilla D, Touma Z, Bookman A, Hiraki L, Ahmad Z, Johnson S, Silverman E, Wither J. Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evidence-for-substantial-immune-activation-in-asymptomatic-ana-positive-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-for-substantial-immune-activation-in-asymptomatic-ana-positive-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology